量子生物(300149.SZ)参股的生和堂拟申请终止在新三板挂牌
格隆汇6月6日丨量子生物(300149.SZ)公布,公司参股公司广东生和堂健康食品股份有限公司(“生和堂”)于2019年6月6日召开的2019年第二次临时股东大会审议通过了《关于申请公司股票在全国中小企业股份转让系统终止挂牌的议案》,其基于所在行业发展状况及其自身业务开展情况,为配合长期经营发展战略和资本市场发展路径的规划,降低运营成本、提高经营决策效率,加快业务拓展,经慎重考虑,生和堂申请股票在全国中小企业股份转让系统终止挂牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.